11 citations
,
August 2017 in “Supportive care in cancer” Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
59 citations
,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
25 citations
,
March 2018 in “Journal of oncology practice” Scalp cooling is an effective and safe way to prevent hair loss from chemotherapy, with manageable side effects and low risk of scalp cancer.
2 citations
,
May 2016 in “Journal of Clinical Oncology” This phase I safety study investigated the efficacy of topical calcitriol (BPM31543) in preventing chemotherapy-induced alopecia (CIA) in up to 31 adult women undergoing taxane-based chemotherapy. The study found that BPM31543 was safe and tolerable, with mild to moderate treatment-related adverse events. The study showed potential activity at higher dosing levels, as hair loss was less severe in patients using doses of ≥ 20 μg/mL compared to lower doses. Specifically, at the ≥ 20 μg/mL dose level, only 43% of participants experienced ≥ 75% hair loss, compared to 85% at the 5/10 μg/mL dose level. Despite these findings, all subjects experienced some degree of hair loss and altered their hairstyles during the study.